| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 49.13M | — |
| Operating expense | — | — |
| Net income | -8.91M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, AX9.F returned -71.8% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -43.5% |
| 1 year | -71.8% |
| 5 years | -68.4% |
| 10 years | -89.4% |
| All-time high | €20.82 (Jun 2014) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in AX9.F would be worth today ›No. Akebia Therapeutics, Inc. has not paid a dividend in the past 12 months.
Akebia Therapeutics, Inc. is part of the Healthcare sector.
Akebia Therapeutics, Inc. has a market cap of 208.72M EUR, based on the latest quote.